β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development
Pathogens · 08.02.2025 · 14 (2) · 168
DOI: 10.3390/pathogens14020168 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathogens, online erschienen am 08.02.2025. Verfasst von Angeliki Katsarou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Athens, Greece. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Anti-Bacterial Agents, beta-Lactams, Gram-Negative Bacteria. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antimicrobial resistance remains a public health problem of global concern with a great health and financial burden. Its recognition as a threat by political leadership has boosted the research and development of new antibiotics and particularly novel combinations of β-lactams/β-lactamase inhibitors against multidrug-resistant (MDR) Gram-negative pathogens, which remain the major concern in clinical practice. The incorporation of ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/cilastatin/relebactam has provided new therapeutic options in the treatment of patients with infections due to MDR pathogens. Cefiderocol along with cefepime/enmetazobactam, avibactam/aztreonam, and sulbactam/durlobactam have been recently added to these agents as therapeutic choices, particularly for metallo-β-lactamase producing Gram-negative bacteria. Currently, many combinations are being studied for their in vitro activity against both serine- and metallo-β-lactamases. However, only a few have advanced through phase 1, 2, and 3 clinical trials. Among them, in this article, we focus on the most promising combinations of cefepime/zidebactam, cefepime/taniborbactam, and imipenem/cilastatin/funobactam, which are currently under investigation in phase 3 trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Athens, Greece.
- Department of Medicine, Hygeia Hospital, 4 Erythrou Stavrou Street, 151 23 Athens, Greece.
- School of Medicine, European University Cyprus, 6 Diogenous Street, 2404 Nicosia, Cyprus.
- Department of Medicine, Tufts University School of Medicine, 145 Harrison Ave, Boston, MA 02111, USA.
Zitieren
APA
Katsarou, A., Stathopoulos, P., Tzvetanova, I. D., Asimotou, C. M., & Falagas, M. E. (2025). β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development. Pathogens, 14(2), 168. https://doi.org/10.3390/pathogens14020168
Vancouver
Katsarou A, Stathopoulos P, Tzvetanova ID, Asimotou CM, Falagas ME. β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development. Pathogens. 2025;14(2):168. doi:10.3390/pathogens14020168
BibTeX
@article{Katsarou2025,
author = {Katsarou, Angeliki and Stathopoulos, Panagiotis and Tzvetanova, Iva D and Asimotou, Christina-Maria and Falagas, Matthew E},
title = {β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development},
journal = {Pathogens},
year = {2025},
volume = {14},
number = {2},
pages = {168},
doi = {10.3390/pathogens14020168}
}
EUVIMED